Development of New Therapeutic Materials for Mitigation of Amyloid Neurotoxicity Associated with Alzheimer’s Disease

Abstract

Alzheimer’s disease (AD), an irreversible brain disorder, first diagnosed more than 100 years ago, still remains a curse to the society, affecting 30 million people worldwide, victimizing one in ten individuals above 65 years’ age, due to lack of efficient therapeutic strategy. Intense research activity suggests that amyloid fibrils originating from self-aggregation of amyloid β peptide having cross-β sheeted conformation are the hallmark of this disease. Hence, inhibition of amyloid aggregation can offer a platform to develop early stage therapeutics against several neurodegenerative diseases including AD.